BY MARKETWIRE
-
Bavarian Nordic sees golden opportunity to supply vaccines for US emergency preparedness
There is a high possibility that 200 million out-of-date smallpox injections will certainly require to be changed in the United States.
-
Bavarian Nordic and collaborator-turned-competitor are going their separate ways
The split issues of Bavarian Nordic’s procurement of an Emergent Biosolutions profile previously this year which remains in straight competitors with the companion.
-
Novo Nordisk launches Wegovy in China
A Novo Nordisk speaker validated the Chinese launch to Reuters, however decreased to talk about the rate distinction in between China and the United States.
-
Bavarian Nordic and collaborator-turned-competitor are going their separate ways
The split is a consequence of Bavarian Nordic’s acquisition of an Emergent Biosolutions portfolio earlier this year which is in direct competition with the partner.
-
Schaeffler plans global use of Agility Robotics’ Digit humanoid
Listen to this article The Digit humanoid transports totes at a Spanx facility shuffle by GXO Logistics in Georgia. | Credit: Agility Robotics Slight print are scarce on the moment, but Agility Robotics has a new strategic partnership. Schaeffler AG, a global leader in motion technology, is making a minority investment into Agility and shopping
-
Coloplast will seek expanded reimbursement coverage for Kerecis wound care products
Unpredictability concerning aids has actually long hung over Coloplast’s share cost.
-
Bavarian Nordic’s smallpox vaccine sales decline by a quarter
Sales of Bavarian Nordic’s smallpox vaccination versus Mpox are unevenly dispersed over monetary quarters, including unpredictability to quarterly contrasts.
-
Coloplast: Kerecis products receive partial reimbursement coverage in the US
Thus far, it does not influence Coloplast’s assumptions for 2024/25, states the firm’s media relationships supervisor.
-
Nordea highlights three potential Lundbeck blockbusters
A drug achieves blockbuster standing when it reaches USD 1bn in gross sales per 12 months.
-
Gubra reports positive results from phase I study on obesity treatment
The outcomes of the SAD research are anticipated to be introduced at a future scientific convention.
